Durvalumab for the management of urothelial carcinoma: a short review on the emerging data and therapeutic potential

Urothelial carcinoma (UC) is the second most frequent urogenital malignancy with high incidence in the United States and Europe. Despite poor prognosis, new treatments have emerged with great efficacy and safety such as immune checkpoint inhibitors. Durvalumab, an anti Programmed Death Ligand 1, has...

Descripción completa

Detalles Bibliográficos
Autores principales: Baldini, Capucine, Champiat, Stéphane, Vuagnat, Perrine, Massard, Christophe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6452813/
https://www.ncbi.nlm.nih.gov/pubmed/31040693
http://dx.doi.org/10.2147/OTT.S141040

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6452813/
https://www.ncbi.nlm.nih.gov/pubmed/31040693
http://dx.doi.org/10.2147/OTT.S141040

Ejemplares similares